MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study.

Qing Yuan ZhangTao SunYong Mei YinHui Ping LiMin YanZhong Sheng TongChristina P OppermannYun Peng LiuRomulo CostaMan LiYing ChengQu Chang OuyangXi ChenNing LiaoXin Hong WuXiao Jia WangJi Feng FengRoberto HeggG B KanakasettyMaria A Coccia-PortugalRu Bing HanYi LuHai Dong ChiZe Fei JiangXi Chun Hu

Published in: Therapeutic advances in medical oncology (2020)

The addition of abemaciclib to ET demonstrated significant and clinically meaningful improvement in PFS and ORR, without new safety signals observed in this population.Trial Registration: ClinicalTrials.gov identifier: NCT02763566.

Keyphrases

phase iii
open label
clinical trial
double blind
phase ii
placebo controlled
study protocol
randomized controlled trial